Craig Hallum Analysts Lift Earnings Estimates for MediWound

MediWound Ltd. (NASDAQ:MDWD) – Research analysts at Craig Hallum lifted their Q3 2026 EPS estimates for MediWound in a research note issued on Wednesday, May 27th. Craig Hallum analyst C. Knickerbocker now anticipates that the biopharmaceutical company will post earnings of ($0.76) per share for the quarter, up from their previous forecast of ($0.82). The consensus estimate for MediWound’s current full-year earnings is ($2.49) per share. Craig Hallum also issued estimates for MediWound’s Q4 2026 earnings at ($0.60) EPS, FY2026 earnings at ($2.35) EPS, Q1 2027 earnings at ($0.60) EPS, Q2 2027 earnings at ($0.56) EPS, Q3 2027 earnings at ($0.50) EPS, Q4 2027 earnings at ($0.45) EPS and FY2027 earnings at ($2.11) EPS.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.42. MediWound had a negative net margin of 180.30% and a negative return on equity of 67.22%. The business had revenue of $1.48 million during the quarter, compared to the consensus estimate of $3.37 million. During the same period in the previous year, the business earned ($0.07) earnings per share.

MDWD has been the subject of several other reports. HC Wainwright restated a “buy” rating and set a $36.00 price objective on shares of MediWound in a research report on Thursday, May 28th. Wall Street Zen upgraded shares of MediWound from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 30th. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a research report on Tuesday, April 21st. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $32.00 target price (down from $33.00) on shares of MediWound in a research note on Wednesday, May 27th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $34.00.

MediWound Price Performance

Shares of MDWD opened at $14.45 on Friday. MediWound has a one year low of $13.54 and a one year high of $22.09. The company has a market cap of $185.68 million, a P/E ratio of -6.39 and a beta of 0.16. The firm has a 50 day simple moving average of $16.39 and a two-hundred day simple moving average of $17.31.

Insider Buying and Selling at MediWound

In related news, Director David Morton Fox bought 3,537 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were purchased at an average price of $14.11 per share, with a total value of $49,907.07. Following the completion of the purchase, the director owned 22,283 shares in the company, valued at $314,413.13. This represents a 18.87% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders own 9.20% of the company’s stock.

Institutional Trading of MediWound

A number of hedge funds and other institutional investors have recently modified their holdings of MDWD. Quarry LP bought a new stake in shares of MediWound during the fourth quarter worth $26,000. BNP Paribas Financial Markets grew its stake in shares of MediWound by 90.4% during the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 723 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 649 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 999 shares during the last quarter. Finally, MetLife Investment Management LLC bought a new stake in shares of MediWound during the fourth quarter worth $109,000. Institutional investors own 46.83% of the company’s stock.

MediWound News Roundup

Here are the key news stories impacting MediWound this week:

• Positive Sentiment: Craig Hallum raised its FY2026 EPS estimate for MediWound, suggesting slightly better near-term profitability than previously expected.
• Positive Sentiment: Craig Hallum also increased its Q3 2026 and Q4 2027 EPS estimates, signaling some improvement in its longer-range outlook for the company.
• Positive Sentiment: MediWound recently beat the consensus EPS estimate in its latest quarterly results, which may still provide some support for the stock.
• Neutral Sentiment: Analyst estimates remain deeply negative overall, with MediWound still expected to post losses in 2026 through 2028, limiting the immediate bullish case.
• Negative Sentiment: Maxim Group cut estimates across several periods, including Q2 2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q3 2027, Q4 2027, FY2027, FY2028, and FY2029, reflecting a weaker outlook for earnings growth.
• Negative Sentiment: Craig Hallum lowered its FY2027 estimate, while Maxim also reduced its Q1 2028 and Q4 2027 forecasts, adding to concerns about slower profitability improvement.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.